000 -LEADER |
fixed length control field |
03823cam a22004574a 4500 |
001 - CONTROL NUMBER |
control field |
13403134 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20120703114430.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
031112s2004 njua b 001 0 eng |
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
LC control number |
2003024925 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
1588292282 (alk. paper) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
1592597394 (e-book) |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(DNLM)101197175 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
DNLM/DLC |
Transcribing agency |
DLC |
Modifying agency |
DLC |
042 ## - AUTHENTICATION CODE |
Authentication code |
pcc |
050 00 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
RC271.C5 |
Item number |
A6722 2004 |
060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
Classification number |
QV 269 |
Item number |
A62953 2004 |
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
616.99/4061 |
Edition number |
22 |
245 00 - TITLE STATEMENT |
Title |
Anticancer drug development guide : |
Remainder of title |
preclinical screening, clinical trials, and approval / |
Statement of responsibility, etc |
edited by Beverly A. Teicher, Paul A. Andrews. |
250 ## - EDITION STATEMENT |
Edition statement |
2nd ed. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
Place of publication, distribution, etc |
Totowa, N.J. : |
Name of publisher, distributor, etc |
Humana Press, |
Date of publication, distribution, etc |
c2004. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
xiv, 450 p. : |
Other physical details |
ill. ; |
Dimensions |
26 cm. + |
Accompanying material |
1 CD-ROM (4 3/4 in.) |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc |
Includes bibliographical references and index. |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
High-volume screening / Michel Pagä -- High-throughput screening in industry / Michael D. Boisclair ... [et al.] -- The NCI human tumor cell line (60-cell) screen: concept, implementation, and applications / Michael R. Boyd -- Human tumor screening / Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff -- Murine L1210 and P388 leukemias / William R. Waud -- In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery / Thomas Corbett ... [et al.] -- Human tumor xenograft models in NCI drug development / Michael C. Alley ... [et al.] -- Specialized in vitro/in vivo procedures employed by the NCI in preclinical drug evaluations / Melinda G. Hollingshead ... [et al.] -- |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Patient-like orthotopic metastatic models of human cancer / Robert M. Hoffman -- Preclinical models for combination therapy / Beverly A. Teicher -- Models for biomarkers and minimal residual tumor / Beverly A. Teicher -- Spontaneously occurring tumors in companion animals as models for drug development / David M. Vail and Douglas H. Thamm -- Nonclinical testing: from theory to practice / Denis Roy and Paul A. Andrews -- Nonclinical testing for oncology drug products / Paul A. Andrews and Denis Roy -- Nonclinical testing for oncology biologic products / Carolyn M. Laurenìot, Denis Roy, and Paul A. Andrews -- |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Working with the national cancer institute / Paul Thambi and Edward A. Sausville -- Phase I trial design and methodology for anticancer drugs / Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin -- Phase II trials: conventional design and novel strategies in the era of targeted therapies / Keith T. Flaherty and Peter J. O'Dwyer -- |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Drug development in Europe: the academic perspective / Chris Twelves ... [et al.] -- The phase III clinical cancer trial / Ramzi N. Dagher and Richard Pazdur -- Assessing tumor-related symptoms and health-related quality of life in cancer clinical trials: a regulatory perspective / Judy H. Chiao, Grant Williams, and Donna Griebel -- The role of the oncology drug advisory committee in the FDA review process for oncologic products / Leslie A. Vaccari -- FDA role in cancer drug development and requirements for approval / Susan Flamm Honig. |
538 ## - SYSTEM DETAILS NOTE |
System details note |
Minimum system requirements: Adobe reader 6.0 or later. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Antineoplastic agents |
General subdivision |
Development. |
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Antineoplastic Agents |
General subdivision |
standards. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Clinical Trials. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Drug Approval. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Drug Design. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Drug Evaluation, Preclinical. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Teicher, Beverly A., |
Dates associated with a name |
1952- |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Andrews, Paul A. |
856 41 - ELECTRONIC LOCATION AND ACCESS |
Materials specified |
Table of contents |
Uniform Resource Identifier |
http://www.loc.gov/catdir/toc/ecip0411/2003024925.html |
856 42 - ELECTRONIC LOCATION AND ACCESS |
Materials specified |
Publisher description |
Uniform Resource Identifier |
http://www.loc.gov/catdir/enhancements/fy0825/2003024925-d.html |
925 0# - |
-- |
acquire |
-- |
1 shelf copy |
-- |
policy default |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Books |